Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate

Ítems similars

• Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses
  per: Wetzler, M, et al.
  Publicat: (2015)
• Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors
  per: Nicolini, Franck E., et al.
  Publicat: (2013)
• Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib
  per: Cortes, Jorge E., et al.
  Publicat: (2013)
• Final Analysis of Efficacy and Safety of Omacetaxine Mepesuccinate in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML): 24-Month Minimum Follow-Up Results
  per: Cortes, Jorge, et al.
  Publicat: (2015)
• Updated Product Label Allows Home Administration of Omacetaxine Mepesuccinate
  per: Shen, Ann Q., et al.
  Publicat: (2014)